Cerus (CERS) Expected to Announce Earnings on Thursday

Cerus (NASDAQ:CERS) will likely be announcing its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $47.44 million for the quarter.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Price Performance

NASDAQ CERS opened at $1.36 on Thursday. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus has a 1-year low of $1.12 and a 1-year high of $2.54. The stock has a market capitalization of $253.23 million, a price-to-earnings ratio of -12.39 and a beta of 1.70. The business’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.65.

Insider Buying and Selling

In other news, COO Vivek K. Jayaraman sold 29,985 shares of Cerus stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $43,478.25. Following the sale, the chief operating officer now owns 1,477,330 shares in the company, valued at $2,142,128.50. This trade represents a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO William Mariner Greenman sold 23,023 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $1.55, for a total transaction of $35,685.65. Following the transaction, the chief executive officer now directly owns 3,230,000 shares of the company’s stock, valued at $5,006,500. The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 441,150 shares of company stock valued at $665,210. Company insiders own 3.40% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.